ConductScience.org, home

Paper42663270

Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.

Abhishek A and 17 others. Health Technol Assess, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study. Papers, record 42663270. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42663270

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Blood-test monitoring strategies for patients established on immune-suppressing drugs: a mixed-methods study.
PubMed
Journal
Health Technol Assess
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-09-09
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Drug MonitoringMajor topic
Hematologic TestsMajor topic
Immunosuppressive AgentsMajor topic
Adult
Aged
Female
Humans
Male
Middle Aged
Cost-Benefit Analysis
Cost-Effectiveness Analysis
Mercaptopurine
Methotrexate
Models, Economic
United Kingdom

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05458531Monitoring of Inflammatory ConditionsDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References360

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121722149Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients.Aliment Pharmacol Ther2011https://conductscience.org/library/papers/21722149PubMed
226905864
A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.
Ann Rheum Dis2017https://conductscience.org/library/papers/26905864PubMed
337431434Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD).Rheumatol Adv Pract2023https://conductscience.org/library/papers/37431434PubMed
428652663Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study.World J Gastroenterol2017https://conductscience.org/library/papers/28652663PubMed
525351370
Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
Health Technol Assess2014https://conductscience.org/library/papers/25351370PubMed
67851193Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.Dig Dis Sci1995https://conductscience.org/library/papers/7851193PubMed
728450313Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.Ann Rheum Dis2017https://conductscience.org/library/papers/28450313PubMed
89330927Long-term treatment of destructive rheumatoid arthritis with methotrexate.J Rheumatol1997https://conductscience.org/library/papers/9330927PubMed
92056950174-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis.Arthritis Res Ther2010https://conductscience.org/library/papers/20569501PubMed
1016402217Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events.Rheumatol Int2006https://conductscience.org/library/papers/16402217PubMed
1130137552The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis.Rheumatology (Oxford)2019https://conductscience.org/library/papers/30137552PubMed
1219665644Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.Lancet2009https://conductscience.org/library/papers/19665644PubMed
1331388915Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis.J Gen Intern Med2019https://conductscience.org/library/papers/31388915PubMed
1411096165A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med2000https://conductscience.org/library/papers/11096165PubMed
1515882242Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom.Aliment Pharmacol Ther2005https://conductscience.org/library/papers/15882242PubMed
167872274Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.Am J Gastroenterol1995https://conductscience.org/library/papers/7872274PubMed
1735702565Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.Rheumatol Adv Pract2022https://conductscience.org/library/papers/35702565PubMed
1824609758Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort.Clin Rheumatol2014https://conductscience.org/library/papers/24609758PubMed
1927484275British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016.Br J Dermatol2016https://conductscience.org/library/papers/27484275PubMed
2035256384Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study.Br J Gen Pract2022https://conductscience.org/library/papers/35256384PubMed

See all 360 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42663270

GET https://conductscience.org/api/papers/v1/42663270/references?page=2